GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $0.300 $0.440 Tuesday, 16th Apr 2024 GLMD stock ended at $0.354. This is 5.80% less than the trading day before Monday, 15th Apr 2024. During the day the stock fluctuated 11.78% from a day low at $0.331 to a day high of $0.370.
90 days $0.300 $0.466
52 weeks $0.260 $5.63

Historical Galmed Pharmaceuticals Ltd. prices

Date Open High Low Close Volume
2024-04-16 $0.370 $0.370 $0.331 $0.354 96 629
2024-04-15 $0.419 $0.419 $0.360 $0.376 87 730
2024-04-12 $0.430 $0.430 $0.370 $0.419 161 442
2024-04-11 $0.430 $0.430 $0.410 $0.420 159 373
2024-04-10 $0.405 $0.440 $0.380 $0.400 296 428
2024-04-09 $0.400 $0.410 $0.370 $0.389 322 995
2024-04-08 $0.390 $0.431 $0.373 $0.396 1 828 982
2024-04-05 $0.322 $0.340 $0.322 $0.339 1 002 239
2024-04-04 $0.327 $0.348 $0.322 $0.330 32 972
2024-04-03 $0.330 $0.340 $0.323 $0.327 42 677
2024-04-02 $0.330 $0.336 $0.315 $0.324 50 296
2024-04-01 $0.340 $0.348 $0.316 $0.316 89 569
2024-03-28 $0.349 $0.349 $0.320 $0.346 41 109
2024-03-27 $0.320 $0.340 $0.320 $0.330 15 989
2024-03-26 $0.324 $0.327 $0.320 $0.320 45 824
2024-03-25 $0.317 $0.326 $0.302 $0.320 134 875
2024-03-22 $0.319 $0.328 $0.307 $0.311 63 713
2024-03-21 $0.305 $0.318 $0.305 $0.316 53 970
2024-03-20 $0.315 $0.320 $0.300 $0.305 78 246
2024-03-19 $0.320 $0.329 $0.303 $0.313 80 083
2024-03-18 $0.300 $0.350 $0.300 $0.311 295 239
2024-03-15 $0.410 $0.410 $0.301 $0.305 3 450 208
2024-03-14 $0.360 $0.360 $0.320 $0.349 34 062
2024-03-13 $0.370 $0.370 $0.350 $0.360 20 165
2024-03-12 $0.390 $0.390 $0.360 $0.360 34 803
Click to get the best stock tips daily for free!

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinica... GLMD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT